natgillin/translations-raw huggingface dataset:
The European Medicines Agency has deferred the obligation to submit the results of studies with Cayston in one or more subsets of the paediatric population in cystic fibrosis patients with Pseudomonas aeruginosa pulmonary infection/colonisation (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Cayston za eno ali več podskupin pediatrične populacije bolnikov s cistično fibrozo z okužbo/kolonizacijo z bakterijo Pseudomonas aeruginosa (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Cayston was evaluated over a period of 28-days of treatment (one course) in two randomised, doubleblind, placebo-controlled, multicentre studies (CP-AI-005 and CP-AI-007).
Zdravilo Cayston so ocenili v 28 dneh zdravljenja (en cikel zdravljenja) v dveh randomiziranih, dvojno-slepih, s placebom kontroliranih, multicentričnih študijah (CP-AI-005 in CP-AI-007).
This pack contains one Altera Nebuliser Handset.
Ta paket vsebuje en komplet z nebulatorjem Altera.
For complete details on cleaning and disinfecting refer to the manufacturer's instructions for use provided with your Altera Nebuliser Handset.
Za vse podrobnosti o čiščenju in razkužitvi preberite proizvajalčeva navodila, ki ste jih prejeli s kompletom z nebulatorjem Altera.
An Altera Nebuliser Handset containing an Altera Aerosol Head connected to an eFlow Control Unit of the type 178 (eFlow rapid) or type 678 (eBase Controller).
komplet z nebulatorjem Altera, ki vsebuje glavo za izdelavo aerosola Altera, povezan s kontrolno enoto eFlow vrste 178 (eFlow rapid) ali vrste 678 (kontrolnik eBase).
Do not try to take Cayston using any other type of nebuliser handset (including the eFlow rapid handset).
Zdravila Cayston ne uporabljajte z nobeno drugo vrsto kompleta z nebulatorjem (vključno s kompletom eFlow rapid).
Step D: When the metal seal opens, continue to slowly pull on the blue cap in a counterclockwise direction until the metal seal is completely removed.
Korak D: Ko se kovinsko tesnilo odpre, še naprej počasi vlecite modro zaporko v obratni smeri urnega kazalca, dokler kovinskega tesnila povsem ne odstranite.
Cystic fibrosis in the lungs leads to clogging them with thick sticky mucus.
Cistična fibroza v pljučih povzroči njihovo zamašitev z lepljivo sluzjo.
Patients participating in these studies could subsequently receive multiple courses of Cayston in an open-label follow-on study (CP-AI-006).
Bolniki, ki so sodelovali v teh študijah, so lahko nato prejeli več ciklov zdravljenja z zdravilom Cayston v odprti nadaljevalni študiji (CP-AI-006).
injection in rats at daily doses up to 750 mg/kg without adverse effects.
perinatalnega in postnatalnega za razvoja pri dnevnih odmerkih do 750 mg/kg brez neželenih učinkov.
Patients treated with aztreonamexperienced a longer time to need for i.v.
Bolniki, zdravljeni z aztreonamom, dalj časa niso potrebovali i.v.
The serum half-life of aztreonam averaged 1.7 hours in subjects with normal renal function, independent of the dose and route.
Razpolovni čas aztreonama v serum je bil povprečno 1,7 ure pri osebah z normalnim delovanjem ledvic, ne glede na odmerek in pot uporabe.
If there is more than a few drops of liquid left, replace the medicine cap and restart treatment.
Če vidite več kot nekaj kapljic tekočine, ponovno namestite pokrov za zdravilo in nadaljujte z zdravljenjem.
Patients participating in this study in Europe who completed at least 1 course of Cayston or TNS during the randomised phase could subsequently receive up to three 28-day courses of Cayston in an open-label extension phase.
Bolniki, ki so sodelovali v tej študiji v Evropi in so zaključili vsaj 1 cikel zdravljenja z zdravilom Cayston ali RTN med randomizirano fazo, so lahko nato prejeli do tri 28-dnevne cikle zdravljenja z zdravilom Cayston v odprti podaljšani fazi.
If you take more Cayston than you should
Če ste uporabili večji odmerek zdravila Cayston, kot bi smeli
Cross-reactivity may occur in patients with a history of allergy to beta-lactam antibiotics, such as penicillins, cephalosporins, and/or carbapenems.
Navzkrižne reakcije se lahko pojavijo pri bolnikih z anamnezo alergij na betalaktamske antibiotike kot so penicilini, cefalosporini in/ali karbapenemi.
Nebulised therapies, including Cayston, may be associated with bronchospasm (an acute reduction of ≥ 15% in FEV1).
Zdravljenje z nebulatorjem, vključno z zdravilom Cayston, je lahko povezano z bronhospazmom (akutno zmanjšanje FEV1 ≥ 15%).
Assessment of adverse reactions is based on experience in four Phase 3 clinical studies involving CF patients with chronic P. aeruginosa infection and post-marketing spontaneous reporting.
Ocena neželenih učinkov temelji na izkušnjah v štirih kliničnih študijah faze 3, v katere so bili vključeni bolniki s CF s kronično okužbo z bakterijo P. aeruginosa, in na spontanih poročilih iz obdobja trženja.
Approximately 10% of the total inhaled aztreonamdose is excreted in the urine as unchanged drug, as compared to 60-65% following intravenous administration of aztreonam for injection.
Približno 10% celokupnega odmerka inhaliranega aztreonama se izloči v urinu v obliki nespremenjenega zdravila, v primerjavi s 60-65% po intravenskem dajanju aztreonama za injiciranje.
Make sure the Altera Nebuliser Handset is on a flat, stable surface.
Komplet z nebulatorjem Altera zagotovo postavite na ravno, stabilno površino.
Bronchospasm has been reported after Cayston administration (see section 4.8).
O bronhospazmu so poročali po dajanju zdravila Cayston (glejte poglavje 4.8).
Intravenous aztreonam is not suitable for inhalation.
Aztreonam za intravensko uporabo ni primeren za inhaliranje.
Pharmacokinetic studies have not been performed in patients with renal or hepatic impairment.
Farmakokinetičnih študij pri bolnikih z okvarjenim delovanjem ledvic ali jeter niso opravili.
Aztreonam exhibits activity in vitro against gram-negative aerobic pathogens, including P. aeruginosa.
Aztreonam kaže in vitro aktivnost proti gram-negativnim aerobnim povzročiteljem bolezni, vključno s P. aeruginosa.
Lung function test decreased has been reported with use of Cayston, but was not associated with a sustained decrease in FEV1 (see section 5.1).
Pri uporabi zdravila Cayston so poročali o poslabšanju testa pljučne funkcije, vendar ni bilo povezano s trajnim zmanjšanjem FEV1 (glejte poglavje 5.1).
- Do not use the solvent or prepared Cayston if it is cloudy or if there are particles in the solution.
- Ne uporabljajte vehikla ali pripravljenega zdravila Cayston, če je motno ali če v raztopini opazite delce.
For storage conditions of the reconstitued medicinal product, see section 6.3.
Za pogoje shranjevanja po rekonstituciji zdravila glejte poglavje 6.3.
Cayston is not expected to affect your ability to drive or use machines.
Ne pričakuje se, da bi zdravilo Cayston vplivalo na sposobnost vožnje ali upravljanja strojev.
To re-start the treatment, press and hold the On/Off button for one full second and then restart the treatment.
Za ponovni začetek zdravljenja pritisnite gumb za vklop/izklop in ga držite eno sekundo, nato pa nadaljujte z zdravljenjem.
In GS-US-205-0110, 268 patients with CF and chronic P. aeruginosa lung infection were randomised and received Cayston (n = 136) or TNS (n = 132).
V študiji GS-US-205-0110 je bilo randomiziranih 268 bolnikov s CF in kronično pljučno okužbo s P. aeruginosa, ki so prejemali zdravilo Cayston (n = 136) ali TNS (n = 132).
Loss of susceptibility to aztreonam in CF patients with P. aeruginosa occurs either through selection of strains with mutations located on the chromosome or rarely through acquisition of plasmid/integron mediated genes.
Do izgube občutljivosti na aztreonam pri bolnikih s CF, okuženih s P. aeruginosa, pride bodisi z izbiro sevov z mutacijami na kromosomu, ali redko s pridobivanjem genov prek plazmidov/integronov.
Following reconstitution, Cayston is a clear, colourless to slightly coloured solution.
Po rekonstituciji je zdravilo Cayston bistra, brezbarvna do rahlo obarvana raztopina.
Therefore, and because of low oral absorption, aztreonam exposure in breast-fed infants due to mothers receiving Cayston is likely to be extremely low.
Zaradi tega in zaradi nizke peroralne absorpcije je verjetnost izpostavljenosti dojenih otrok aztreonamu pri materah, ki uporabljajo zdravilo Cayston, izjemno majhna.
Be sure to completely empty the vial.
Povsem izpraznite vialo.
In studies of up to nine 28-day courses of Cayston therapy, no increases of clinical significance were observed in the treatment-emergent isolation of other gram-negative bacterial respiratory pathogens (Burkholderia species, Stenotrophomonas maltophilia and Alcaligenes species).
V študijah do devetih 28-dnevnih ciklov zdravljenja z zdravilom Cayston niso opazili povečanja klinične pomembnosti v izolaciji drugih gramnegativnih bakterijskih respiratornih povzročiteljev, ki so se pojavili v povezavi z zdravljenjem (vrste Burkholderia, Stenotrophomonas maltophilia in vrste Alcaligenes).
Aztreonam for injection must not be used in the Altera or other nebulisers.
Aztreonam za injiciranje se ne sme uporabljati v nebulatorju Altera ali drugih nebulatorjih.
An acute reduction of ≥ 15% in FEV1 is a complication associated with nebulised therapies, including Cayston (see section 4.4).
Akutno zmanjšanje FEV1 ≥ 15% je zaplet, povezan z zdravljenjem z nebulatorjem, ki vključuje tudi zdravilo Cayston (glejte poglavje 4.4).
A few drops of medicine may remain in the reservoir at the end of treatment.
V vsebniku za zdravilo sme po koncu zdravljenja ostati nekaj kapljic zdravila.
Cayston should not be used with any other type of handset or aerosol head.
Cayston se ne sme uporabljati z nobeno drugo vrsto kompleta ali glavo za izdelavo aerosola.
If Cayston is to be prescribed to the elderly then the posology is the same as for adults.
Če se zdravilo Cayston predpiše starejšim bolnikom je odmerjanje enako kot pri odraslih.
Cayston has no or negligible influence on the ability to drive or use machines.
Zdravilo Cayston nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Powder vial and solvent ampoule: Store in a refrigerator (2°C - 8°C).
Viala s praškom in ampula z vehiklom: Shranjujte v hladilniku (2 °C - 8 °C).
Patients continued on their baseline medications and whenever indicated additional antibiotics were used in the majority of patients to treat exacerbations.
Kadar je bilo indicirano, so pri večini bolnikov uporabili dodatne antibiotike za zdravljenje eksacerbacij.
A single sputum sample from a CF patient may contain multiple isolates of P. aeruginosa and each isolate may have a different level of in vitro susceptibility to aztreonam.
En sam vzorec izpljunka bolnika s CF lahko vsebuje več izolatov povzročitelja P. aeruginosa in vsak posamezni izolat lahko izkazuje različno raven in vitro občutljivosti na aztreonam.
One hour following a single dose of 75 mg inhaled aztreonam (at approximately peak plasma concentration), the mean plasma level in patients with CF was 0.59 µg/ml.
Eno uro po enem 75-mg odmerku inhaliranega aztreonama (približno pri najvišji koncentraciji v plazmi) je bila srednja raven v plazmi pri bolnikih s CF 0,59 µg/ml.
Step C: While continuing to hold the vial steady with one hand, use the other hand to slowly pull the blue cap in a counterclockwise direction.
Korak C: Medtem ko z eno roko še vedno trdno držite vialo, z drugo roko počasi vlecite modro zaporko v obratni smeri urnega kazalca.
The adverse reactions considered at least possibly related to treatment from clinical study and postmarketing experience are listed below by body system organ class and frequency.
Neželeni učinki, za katere se na podlagi kliničnih študij in izkušenj med trženjem meni, da obstaja vsaj možna povezanost z zdravljenjem, so navedeni spodaj glede na organske sisteme in pogostnost.
The vial is then gently swirled until contents have completely dissolved.
Vialo nežno obračajte, dokler se vsebina popolnoma ne raztopi.
In a Phase 2 open-label study (GS-US-205-0162), 105 paediatric patients aged 3 months to < 18 years (24 patients aged 3 months to < 2 years; 25 patients aged 2 to < 6 years; 56 patients aged 6 to < 18 years) with CF and documented initial/new onset P. aeruginosa infection/colonisation received Cayston 3 times a day for a single course of 28 days.
V odprti študiji faze 2 (GS-US-205-0162) je 105 pediatričnih bolnikov, starih od 3 mesece do < 18 let (24 bolnikov, starih od 3 mesece do < 2 leti; 25 bolnikov, starih od 2 do < 6 let; 56 bolnikov, starih 6 do < 18 let) s CF in dokumentirano novo/ponovljeno okužbo/kolonizacijo z bakterijo P. aeruginosa v enem 28-dnevnem ciklu prejemalo zdravilo Cayston 3-krat na dnevno.
What Cayston looks like and contents of the pack
Izgled zdravila Cayston in vsebina pakiranja
or inhaled antipseudomonal antibiotics (84 versus 121, p = 0.004) than TNStreated patients.
ali inhalacijskih antibiotikov proti bakterijam Pseudomonas (84 v primerjavi s 121, p = 0,004), kot v skupini, zdravljeni z RTN.
The Phase 2 and 3 placebo-controlled, registrational studies permitted comparison of plasma concentrations 1 hour post dose of Cayston by age (6 to 12 years, 13 to 17 years, and ≥ 18 years).
Registracijske, s placebom kontrolirane študije faze 2 in faze 3 so omogočile primerjavo koncentracij v plazmi 1 uro po odmerku zdravila Cayston glede na starost (6 do 12 let, 13 do 17 let in ≥ 18 let).
In the limited subgroup of patients who received inhaled tobramycin for less than 84 days in the previous 12 months (n = 40), lung function improvements at Day 28 and across three 28-day treatment courses were numerically smaller among aztreonam-treated patients than TNS-treated patients.
V omejeni podskupini bolnikov, ki so prejemali inhalirani tobramicin manj kot 84 dni v predhodnih 12 mesecih (n = 40), so bila izboljšanja pljučne funkcije 28. dan in v treh 28-dnevnih ciklih zdravljenja številčno manjša v skupini bolnikov, zdravljenih z aztreonamom, kot v skupini bolnikov, zdravljenih z RTN.
CP-AI-005 enrolled 246 adult (predominantly) and paediatric patients.
CP-AI-005 V študiji CP-AI-005 je sodelovalo 246 odraslih (v večini) in pediatričnih bolnikov.
Solvent: 1 ml low density polyethylene ampoule.
Vehikel: 1 ml ampula iz polietilena nizke gostote.
Aztreonam is known to be excreted renally and therefore administration of Cayston in patients with renal impairment (serum creatinine > 2 times upper limit of normal) should be undertaken with caution.
Znano je, da se aztreonam izloča preko ledvic, zato je treba pri bolnikih z okvarjenim delovanjem ledvic (kreatinin v serumu > 2-kratna zgornja meja normale) zdravilo Cayston uporabljati previdno.
Do not use this medicine if you notice that the package has been tampered with.
Ne uporabljajte tega zdravila, če opazite znake odpiranja embalaže.
However, decreased P. aeruginosa susceptibility was not predictive of clinical efficacy of Cayston during the study.
Vendar pa na podlagi zmanjšane občutljivosti na povzročitelja P. aeruginosa ni bilo mogoče napovedati klinične učinkovitosti zdravljenja z zdravilom Cayston v obdobju študije.
A total of 79 patients who completed a 28-day treatment course and who did not receive an additional antipseudomonal antibiotic during the treatment period were evaluable 6 months after the end of treatment; of these, 58.2% (n = 46) remained free of P. aeruginosa throughout this time period.
Skupaj 79 bolnikov, ki so končali 28-dnevni cikel zdravljenja, in ki niso prejemali dodatnih antipsevdomonskih antibiotikov v obdobju zdravljenja, je bilo 6 mesecev po koncu zdravljenja mogoče oceniti; med njimi jih bakterije P. aeruginosa ves čas tega obdobja ni imelo 58,2 % (n = 46).
The occurrence of rash may be indicative of an allergic reaction to aztreonam.
Pojav izpuščaja je lahko znak alergijske reakcije na aztreonam.
Aztreonam binds to penicillin-binding proteins of susceptible bacteria, which leads to inhibition of bacterial cell wall synthesis, followed by filamentation and cell lysis.
Aztreonam se veže na beljakovine občutljivih bakterij, ki vežejo penicilin, kar povzroča zaviranje sinteze bakterijskih celičnih sten, ki ji sledita filamentacija in razpad celic.
Solvent for Cayston Sodium Chloride 0.17%
vehikel za zdravilo Cayston natrijev klorid 0,17 %
A 104-week rat inhalation toxicology study to assess the carcinogenic potential of ascending doses of aztreonamdemonstrated no drug-related increase in malignant tumours.
V 104-tedenski študiji inhalacijske toksičnosti pri podganah za ocenitev kancerogenega potenciala naraščajočih odmerkov aztreonama niso opazili z zdravilom povezanega povečanja malignih tumorjev.
antipseudomonal antibiotics related to respiratory events compared to TNS-treated patients (p = 0.0025).
antibiotikov proti bakterijam Pseudomonas, povezanih z respiratornimi dogodki, v primerjavi z bolniki, zdravljenimi z RTN (p = 0,0025).
Press down and turn the cap clockwise as far as it will go (Figure 3b).
Pokrov za zdravilo pritisnite navzdol in ga obračajte v smeri urnega kazalca, dokler gre (slika 3b).
Paediatric patients had clinical improvements with aztreonamas determined by an increase in FEV1, improvement in CFQ-R respiratory symptoms scores and decline in P. aeruginosa sputum density.
Pri pediatričnih bolnikih so bila klinična izboljšanja z aztreonamom ugotovljena s povečanjem FEV1, izboljšanjem rezultatov respiratornih simptomov CFQ-R in zmanjšanjem gostote P. aeruginosa v izpljunku.
It's best to use Cayston immediately after you have made up the solution.
Najboljše je, da zdravilo Cayston uporabite takoj, ko ste pripravili raztopino.
Treatment-emergent persistent isolation (defined as absent at screening/baseline then present at 3 or more subsequent consecutive visits) of MSSA occurred in 6% of aztreonam-treated patients compared to 3% of TNS-treated patients.
Persistentna izolacija MSSA, ki se je pojavila ob zdravljenju (opredeljena kot odsotnost pri presejanju/izhodišču, nato pa prisotna pri 3 ali več naslednjih zaporednih obiskih), se je pojavila pri 6 % bolnikov, zdravljenih z aztreonamom, v primerjavi s 3 % bolnikov, zdravljenih z RTN.
Cayston contains the active substance aztreonam.
Zdravilo Cayston vsebuje učinkovino aztreonam.
Do not stop taking Cayston without first talking to your doctor.
Ne prenehajte jemati zdravila Cayston brez posveta z zdravnikom.
The known mechanism of resistance to aztreonam mediated by acquisition of genes involves acquisition of extended spectrum beta-lactam enzymes (ESBLs) that hydrolyse the fourmember, nitrogen-containing ring of aztreonam.
Znan mehanizem odpornosti na aztreonam, ki ga povzroči pridobivanje genov, zajema pridobivanje betalaktam encimov z razširjenim spektrom (ESBL - extended spectrum beta-lactam enzymes), ki hidrolizira štiričlanski obroč aztreonama, ki vsebuje dušik.
Do not completely tear through the metal seal.
Kovinskega tesnila ne smete v celoti pretrgati.
The use of Cayston in paediatric CF patients has been associated with haemoptysis during treatment cycles and could have aggravated underlying conditions.
Uporaba zdravila Cayston pri pediatričnih bolnikih s CF je bila v ciklih zdravljenja povezana s hemoptizo in je lahko poslabšala osnovne bolezni.
Safely dispose of the metal seal.
Varno odstranite kovinsko tesnilo.
Sodium chloride Water for injections
Vehikel natrijev klorid voda za injekcije
Gently tap the amber vial containing the Cayston so that the powder settles at the bottom.
Nežno potolcite po rjavi viali, ki vsebuje zdravilo Cayston, da se prašek usede na dnu.
Replacing the Altera Nebuliser Handset
Zamenjava pršilnika nebulatorja Altera
Next, gently swirl the vial until the powder has completely dissolved and the liquid is clear.
Nato nežno obračajte vialo, dokler se prašek povsem ne raztopi in ne dobite bistre tekočine.
Development of resistance during inhaled aztreonam therapy could limit treatment options during acute exacerbations.
Razvoj odpornosti med inhalacijsko terapijo z aztreonamom lahko omeji možnosti zdravljenja med akutnimi poslabšanji.
The in vitro antimicrobial susceptibility test methods used for parenteral aztreonam therapy can be used to monitor the susceptibility of P. aeruginosa isolated from CF patients.
Metode preskušanja antimikrobne občutljivosti in vitro, uporabljene za parenteralno terapijo z aztreonamom, se lahko uporabljajo za nadziranje občutljivosti povzročitelja P. aeruginosa, izoliranega iz bolnikov s CF.
Tabulated summary of adverse reactions
Tabelarični povzetek neželenih učinkov
Aztreonam is not extensively metabolised.
Aztreonam se ne presnavlja obsežno.
Non-clinical data for aztreonam for injection about fertility do not indicate any adverse effects.
Predklinični podatki o vplivu aztreonama za injiciranje na plodnost ne kažejo na neželene učinke.
Rash has been reported with the use of Cayston and may be indicative of an allergic reaction to aztreonam (see section 4.4).
Poročali so o izpuščaju, ki se je pojavil po uporabi zdravila Cayston, kar je lahko znak alergijske reakcije na aztreonam (glejte poglavje 4.4).
The liquid is squeezed out of one solvent ampoule into the glass vial.
Tekočino iz ene ampule z vehiklom iztisnite v stekleno vialo.
- The solvent ampoule contains water for injections and sodium chloride.
- Ampula z vehiklom vsebuje vodo za injekcije in natrijev klorid.
Preparing your Cayston for inhalation
Priprava zdravila Cayston za inhaliranje
In the two Phase 3 placebo-controlled clinical studies where patients received Cayston for 28 days, the most frequently occurring adverse reactions to Cayston were cough (58%), nasal congestion (18%), wheezing (15%), pharyngolaryngeal pain (13.0%), pyrexia (12%) and dyspnoea (10%).
V dveh s placebom kontroliranih kliničnih študijah faze 3, v katerih so bolniki zdravilo Cayston prejemali 28 dni, so bili najpogostejši neželeni učinki povezani z zdravilom Cayston kašelj (58%), zamašen nos (18%), sopenje (15%), faringolaringalna bolečina (13%), pireksija (12%) in dispneja
Bronchospasm
Bronhospazem
During the 6-month randomised phase of study GS-US-205-0110, treatment-emergent isolation of MSSA and MRSA was observed more commonly among aztreonam-treated patients than Tobramycin Nebuliser Solution (TNS)-treated patients.
Med 6-mesečno randomizirano fazo študije GS-US-205-0110, so izolacijo MSSA in MRSA, ki se je pojavila ob zdravljenju, pri bolnikih, zdravljenih z aztreonamom, opazili bolj pogosto kot pri bolnikih, zdravljenih z raztopino tobramicina za nebulator (RTN).
Since the plasma concentration of aztreonam following administration of Cayston (75 mg) is approximately 0.6 µg/ml, compared to serum levels of 54 µg/ml following administration of aztreonam for injection (500 mg), no safety issues associated with aztreonam overdose are anticipated.
Ker je koncentracija aztreonama v plazmi po uporabi zdravila Cayston (75 mg) približno 0,6 µg/ml v primerjavi z ravnjo v serumu 54 µg/ml po uporabi aztreonama za injiciranje (500 mg), ni za pričakovati težav z varnostjo, povezanih s prevelikim odmerjanjem aztreonama.
If you stop taking Cayston
Če ste prenehali uporabljati zdravilo Cayston
cough, nasal congestion, wheezing, pharyngolaryngeal pain, dyspnoea
kašelj, zamašen nos, sopenje, faringolaringalna bolečina, dispneja
An association between persistent isolation of MRSA and more severe disease and increased mortality has been reported in the literature.
V literaturi poročajo o povezavi med persistentno izolacijo MRSA in hujšo boleznijo in povečano smrtnostjo.
Treatment-emergent intermittent isolation of MRSA occurred in 7% of aztreonam-treated patients compared to 1% of TNS-treated patients and treatment-emergent persistent isolation of MRSA occurred in 3% of aztreonam-treated patients compared to no TNS-treated patients.
Prehodna izolacija MRSA, ki se je pojavila ob zdravljenju, se je pojavila pri 7 % bolnikov, zdravljenih z aztreonamom, v primerjavi z 1 % bolnikov, zdravljenih z RTN in persistentna izolacija MRSA, ki se je pojavila ob zdravljenju, se je pojavila pri 3 % bolnikov, zdravljenih z aztreonamom, v primerjavi z nič bolniki, zdravljenimi z RTN.